Skip to main content
. Author manuscript; available in PMC: 2018 Dec 17.
Published in final edited form as: Mol Pharm. 2018 Apr 12;15(9):3717–3722. doi: 10.1021/acs.molpharmaceut.8b00126

Table 1.

summarizes the data from the 5 patients that are the subject of this study.

Treatment Patient
information
Pretreatment
cellularity
Posttreatment
cellularity
Patient
outcome
Hypofractionated radiation 10 year old, male, Labrador Tumor 68%
Lymph/mono 12%
PMN 2%
Stroma 19%
Tumor 55%
Lymph/mono 15%
PMN 4%
Stroma 26%
Euthanized due to local and metastatic cancer; 5 months post treatment
Magnetic nanoparticle hyperthermia 11 year old, male, Siberian Husky Tumor 70%
Lymph/mono 11%
PMN 2%
Stroma 17%
Tumor 26%
Lymph/mono 18%
PMN 18%
Stroma 38%
Euthanized due to local and metastatic cancer; 26 months post treatment
Hypofractionated radiation + virus like particles 7 year old male Labrador Tumor 74%
Lymph/mono 16%
PMN 1%
Stroma 13%
Tumor 18%
Lymph/mono 21%
PMN 13%
Stroma 48%
Tumor free when euthanized due to GI torsion; 5 months post treatment
Hypofractionated radiation + virus like particles 12 year old, female Beagle Tumor 87%
Lymph/mono 6%
PMN 1%
Stroma 13%
Tumor 29%
Lymph/mono 45%
PMN 9%
Stroma 17%
Alive and tumor free; 20 months post treatment
Hypofractionated radiation + virus like particles+ magnetic nanoparticle hyperthermia 9 year old, male Rottweiler Tumor 69%
Lymph/mono 14%
PMN 2%
Stroma 25%
Tumor 21%
Lymph/mono 22%
PMN 11%
Stroma 46%
Tumor free when euthanized due to non-cancer issue: 10 months post treatment